Regulatory FDA issues complete response letter to Replimune’s RP1 for melanoma Pharmaceutical TechnologyThe FDA has issued a complete response letter to Replimune's biologics license application concerning the RP1 therapy.RegulatoryOncologyRead full story pharminent April 13, 2026 (Last updated: April 13, 2026) Pharmaceutical Technology The FDA has issued a complete response letter to Replimune’s biologics license application concerning the RP1 therapy. RegulatoryOncologyRead full story Post navigation Previous: FDA hands another rejection to Replimune’s melanoma therapyNext: Data backs GSK’s ovarian cancer blockbuster hopes Related Stories Regulatory Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa pharminent August 20, 2026 Regulatory Regeneron wins FDA approval to challenge Ipsen for rare bone disease market pharminent August 20, 2026 Regulatory FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy pharminent August 20, 2026
